IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination

Simple item page
dc.contributor.authorMeltendorf, Stefan
dc.contributor.authorVogel, Katrin
dc.contributor.authorThurm, Christoph
dc.contributor.authorPrätsch, Florian
dc.contributor.authorReinhold, Annegret
dc.contributor.authorFärber, Jacqueline
dc.contributor.authorHeuft, Hans-Gert
dc.contributor.authorKaasch, Achim J.
dc.contributor.authorHachenberg, Thomas
dc.contributor.authorWeinzierl, Stefan
dc.contributor.authorSchraven, Burkhart
dc.contributor.authorReinhold, Dirk
dc.contributor.authorBrunner-Weinzierl, Monika C.
dc.contributor.authorLingel, Holger
dc.date.accessioned2022-12-23T09:26:00Z
dc.date.available2022-12-23T09:26:00Z
dc.date.issued2022-10-22
dc.description.abstractAfter recovery, mild and severe COVID-19 diseases are associated with long-term effects on the host immune system, such as prolonged T-cell activation or accumulation of autoantibodies. In this study, we show that mild SARS-CoV-2 infections, but not SARS-CoV-2 spike mRNA vaccinations, cause durable atopic risk factors such as a systemic Th2- and Th17-type environment as well as activation of B cells responsive of IgE against aeroallergens from house dust mite and mold. At an average of 100 days post mild SARS-CoV-2 infections, anti-mold responses were associated with low IL-13 levels and increased pro-inflammatory IL-6 titers. Acutely severely ill COVID-19 patients instead showed no evidence of atopic reactions. Considering convalescents of mild COVID-19 courses and mRNA-vaccinated individuals together, IL-13 was the predominant significantly upregulated factor, likely shaping SARS-CoV-2 immunity. Application of multiple regression analysis revealed that the IL-13 levels of both groups were determined by the Th17-type cytokines IL-17A and IL-22. Taken together, these results implicate a critical role for IL-13 in the aftermath of SARS-CoV-2 mild infections and mRNA vaccinations, conferring protection against airway directed, atopic side reactions that occur in mildly experienced COVID-19.en
dc.identifier.eissn1521-4141
dc.identifier.issn0014-2980
dc.identifier.urihttps://depositonce.tu-berlin.de/handle/11303/17877
dc.identifier.urihttps://doi.org/10.14279/depositonce-16666
dc.language.isoen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610 Medizin und Gesundheitde
dc.subject.otherallergyen
dc.subject.otherCOVID-19en
dc.subject.othercytokinesen
dc.subject.otherSARS-CoV-2en
dc.subject.othervaccinationen
dc.titleIL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccinationen
dc.typeArticle
dc.type.versionpublishedVersion
dcterms.bibliographicCitation.doi10.1002/eji.202249951
dcterms.bibliographicCitation.issue12
dcterms.bibliographicCitation.journaltitleEuropean Journal of Immunology
dcterms.bibliographicCitation.originalpublishernameWiley
dcterms.bibliographicCitation.originalpublisherplaceNew York, NY
dcterms.bibliographicCitation.pageend1979
dcterms.bibliographicCitation.pagestart1972
dcterms.bibliographicCitation.volume52
dcterms.rightsHolder.referenceCreative-Commons-Lizenz
tub.accessrights.dnbfree
tub.affiliationTechnische Universität Berlin::Fak. 1 Geistes- und Bildungswissenschaften::Inst. Sprache und Kommunikation::FG Audiokommunikation
tub.publisher.universityorinstitutionTechnische Universität Berlin
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Meltendorf_etal_IL‐13_2022.pdf
Size:
2.73 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
4.23 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Publications